Form 8-K - Current report:
SEC Accession No. 0001193125-26-088195
Filing Date
2026-03-03
Accepted
2026-03-03 16:10:24
Documents
12
Period of Report
2026-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K elvn-20260303.htm   iXBRL 8-K 49467
2 EX-99.1 elvn-ex99_1.htm EX-99.1 193621
3 GRAPHIC img107523686_0.gif GRAPHIC 15492
  Complete submission text file 0001193125-26-088195.txt   383392

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elvn-20260303.xsd EX-101.SCH 25088
14 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20260303_htm.xml XML 4753
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 26714146
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)